PHARMACY

Astellas names 2 regional sales execs

BY David Salazar

NORTHBROOK, Ill. — Astellas has named the heads of two regional sales leads The company on Wednesday promoted David Musselman to be area VP sales, primary care and specialty care-east, and named Lynn Gerber area VP sales, primary care and specialty care-west.

“These changes will further support our efforts to ensure we’re providing valuable therapies to patients who need them,” Astellas VP sales, primary care/specialty and hospital, Steve Sabus said. “Both David and Lynn’s demonstrated ability to lead and develop high-performance teams will build on the important relationships and communication that we’ve established with our customers and accounts in key US geographies.”

Musselman’s pharmaceutical sales experience spans 20 years, most recently at Astellas as its director of regional accounts east. In that role, he led a team of regional account managers in the company’s oncology, urology, transplant and antifungal franchises. He joined the company as a Georgia regional sales manager in 2007, followed by his time as area sales director for the southeastern United States. His career began at Pfizer, where he served in various roles, including district manager. In his new role, Musselman will be based in South Carolina, overseeing a team of five sales directors and reporting to Sabus.

Musselman takes over his new role from Gerber, who has been with Astellas since 2003 and has more than 25 years of pharmaceutical industry experience. Before joining Astellas, she worked in sales, marketing and operations roles of increasing responsibility at GSK. Gerber is a member of the Healthcare Businesswomen’s Association and was the winner of its 2015 BA Luminary Award. In her new role she will be based in Illinois, overseeing a team of five sales directors.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Sanofi to acquire Protein Sciences

BY David Salazar

PARIS — Sanofi on Tuesday announced that it would be acquiring vaccine company Protein Sciences for $650 million upfront. The acquisition also would see Sanofi paying an additional $100 million based on certain milestones.

“Protein Sciences was actively looking for an opportunity to grow its business, particularly in the United States,” Protein Sciences president and CEO Manon M.J. Cox said. “As part of Sanofi Pasteur, we expect our Flublok influenza vaccine to benefit from Sanofi Pasteur’s expertise in the field of influenza vaccines.”

The deal would bring Protein Sciences’ recently approved Flublok quadrivalent flu vaccine to its portfolio — bringing the company a non-egg-based flu vaccine.

"The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine," Sanofi EVP and head of the company’s vaccine arm Sanofi Pasteur David Loew said.

Sanofi and Protein Sciences expect the deal to close by the end of the third quarter
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

PrescribeWellness rolls out PrescribeCare to support enhanced pharmacy offerings

BY DSN STAFF

IRVINE, Calif. — Cloud-based software company PrescribeWellness’ latest launch is looking to help support pharmacies expanding their clinical services offerings. PrescribeCare software allows pharmacies to create and share care plans electronically while supporting care coordination and tapping into new and emerging payment models, the company said.

“PrescribeWellness is committed to helping community pharmacies make the paradigm shift from being pill-centric to patient-centric, and enhanced services are an integral part of that,” said Al Babbington, CEO of PrescribeWellness. “PrescribeCare further advances community pharmacies’ ability to identify and manage patient care encounters daily, collaborate more easily with physicians and health systems, and uncover non-dispensing revenue opportunities.”

PrescribeCare, which is included as a no-cost feature for PrescribeWellness users, is built with Pharmacist eCarePlan to allow pharmacies to exchange patient information with other care team members. It can be used to identify what interventions or services a patient would benefit from — including adherence monitoring and coaching, immunizations, compliance packaging, delivery and Medicare plan reviews.

“PrescribeWellness is helping transform the future of pharmacy,” PrescribeWellness VP pharmacy practice innovation Mindy Smith said. “With PrescribeCare, community pharmacists have the tools they need to optimize medication therapy and patient health outcomes by connecting with the primary care provider and healthcare team. It is amazing to be a part of the transformation which will help create new opportunities for community pharmacies.”

PrescribeWellness said PrescribeCare interfaces with more than 50 pharmacy management systems to analyze dispensing data in real time, offering insights into patient needs.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?